Did the FDA ban compounded semaglutide?

While compounded semaglutide is still available, accessing it will be more difficult now that the FDA has declared the semaglutide shortage over. But it should be easier to access approved, commercially-available semaglutide.

Semaglutide is a glucagon-like peptide-1 (GLP-1) agonist, available as the brand-name medications Wegovy, Ozempic, and Rybelsus.

Due to a surge in demand, the Food and Drug Administration (FDA) added injectable semaglutide to the FDA drug shortage list in March 2022. As a result, many compounded semaglutide products quickly became available to address the shortage.

But in February 2025, the FDA determined the semaglutide shortage to be resolved. A host of questions emerged after this announcement. Is compounded semaglutide still available, or is the FDA banning it?

Here we discuss the latest on compounded semaglutide and what the FDA declaration means for accessing it.

No, the FDA isn’t banning compounded semaglutide. But because the semaglutide shortage is declared over, the availability of compounded semaglutide will decrease significantly.

Normally, it’s against the law for a compounding pharmacy to make an “essential copy” of an FDA-approved medication. But there are special exceptions. When the FDA declares a drug shortage, for example, some federal regulations may not apply — including restrictions on compounding copies of approved medications.

After the FDA declared a semaglutide shortage in 2022, many compounding pharmacies and telehealth companies started offering compounded semaglutide to address the gap in availability. These companies could create compounded semaglutide at the same doses as commercially-available semaglutide due to the declared shortage.

However, the FDA announced that the semaglutide shortage was resolved on February 21, 2025. As a result, the FDA will again enforce regulations which prevent compounding semaglutide in most cases.

There are exceptions, though. For example, compounding pharmacies can still make compounded semaglutide at non-standard doses which aren’t commercially available, if your healthcare professional determines you have a specific medical need which cannot be met with the standard product.

Although the availability of compounded semaglutide will drop significantly now that the shortage is declared over, it is still possible to get semaglutide online.

Yes, you still need a prescription to get semaglutide online. By law, medications still require a prescription to be legally dispensed by a pharmacy, even if most of the process occurs online. This applies for both commercially-available and compounded semaglutide.

Possibly, but it’s hard to say for certain.

Compounded medications aren’t approved by the FDA and thus haven’t gone through rigorous clinical trials. This means the FDA doesn’t review compounded semaglutide safety or whether these medications are effective.

It’s also important to note that products marketed as semaglutide online may not actually contain the FDA-approved active ingredient. They may contain untested forms, such as semaglutide acetate, or contain other unregulated ingredients. Buying semaglutide online carries a risk for inadvertently purchasing semaglutide from an unregulated source, which poses risks for your health.

If you’re interested in learning about legitimate sources for obtaining this drug online, check out this How to Get Semaglutide in 2025 article.

In the United States, it’s not exactly clear when generic semaglutide will be available.

Novo Nordisk, the manufacturer of Ozempic, Rybelsus, and Wegovy, owns several patents on semaglutide. The “primary” patent expires in the U.S. in 2031, but Novo Nordisk also has several “secondary” patents which may extend protection through 2033 or beyond. It can take several months or even years for generic competitors to enter the market after a brand drug patent expires.

Generic semaglutide may be available sooner than 2031 outside the U.S. For example, Novo’s primary semaglutide patent is set to expire in 2026 in Canada and China.

It’s important to note that the legal and regulatory landscape, including drug patents, changes over time. The timeline for when generic semaglutide will be available on the market may change based on court decisions regarding drug patents and other legal or regulatory updates.

Possibly. The FDA decision to allow compounded semaglutide at standard doses was made based on semaglutide supply levels at the time. Whether due to surges in demand, supply chain issues, or other problems, a shortage could reoccur sometime in the future. In that case, the FDA could again allow temporary expanded semaglutide compounding to address the shortage.

Although the FDA isn’t banning compounded semaglutide, the agency is enforcing standard regulations regarding compounding now that the semaglutide shortage is over. This means the availability of compounded semaglutide will decrease significantly.

If another shortage occurs in the future, it’s possible the FDA will again allow a temporary expansion of semaglutide compounding.

Disclaimer: Medical News Today has made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or another healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.